Cargando…
Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?
Hypogammaglobulinemia (HGG) is a frequent finding in patients with hematological malignancies, and is commonly described in chronic lymphocytic leukemia (CLL) before or after treatment. We reviewed published literature available online in the last thirty years through Medline search of indexed artic...
Autores principales: | Noto, Alessandro, Cassin, Ramona, Mattiello, Veronica, Bortolotti, Marta, Reda, Gianluigi, Barcellini, Wilma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140292/ https://www.ncbi.nlm.nih.gov/pubmed/37122737 http://dx.doi.org/10.3389/fimmu.2023.1062376 |
Ejemplares similares
-
The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
por: Noto, Alessandro, et al.
Publicado: (2021) -
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
por: Compagno, Nicolò, et al.
Publicado: (2014) -
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia
por: Ohmoto, Akihiro, et al.
Publicado: (2022) -
Lifelong immunoglobulin replacement is not always necessary: A case description of a patient with recurrent infections and hypogammaglobulinemia
por: Napiorkowska-Baran, Katarzyna, et al.
Publicado: (2019) -
AlignRT(®) and Catalyst™ in whole‐breast radiotherapy with DIBH: Is IGRT still needed?
por: Laaksomaa, Marko, et al.
Publicado: (2019)